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The noncovalent binding of various peptide ligands to pp60 sr¢ (Src) SH2 (Src homology 2) 
domain protein (12.9 ku) has been used as a model system for development of electrospray 
ionization mass spectrometry (ESI-MS) as a tool to study noncovalently bound complexes. 
SH2 motifs in proteins are critical in the signal transduction pathways of the tyrosine kinase 
growth factor receptors and recognize phosphotyrosine-containing proteins and peptides. 
ESI-MS with a magnetic sector instrument and array detection has been used to detect he 
protein-peptide complex with low-picomole sensitivity. The relative abundances of the 
multiply charged ions for the complex formed between Src SH2 protein and several 
nonphosphorylated and phosphorylated peptides have been compared. The mass spectrome- 
try data correlate well to the measured binding constants derived from solution-based 
methods, indicating that the mass spectrometry-based method can be used to assess the 
affinity of such interactions. Solution-phase equilibrium constants may be determined by 
measuring the amount of bound and unbound species as a function of concentration for 
construction of a Scatchard graph. ESI-MS of a solution containing Src SH2 with a mixture of 
phosphopeptides showed the expected protein-phosphopeptide complex as the dominant 
species in the mass spectrum, demonstrating the method's potential for screening mixtures 
from peptide libraries. © 1997 American Society for Mass Spectrometry (J Am Soc Mass 
Spectrom 1997, 8, 234-243) 
Introduction 
" '~'~rote in-prote in  interactions are the language of 
| "1  cell biology" [1]. Biochemical events are medi- 
. i .  ated by molecular interactions, either through a
covalent or noncovalent nature. Developing method- 
ologies to study such interactions is important for 
understanding biochemical processes. Electrospray 
ionization mass spectrometry (ESI-MS) has developed 
as an important tool for characterizing large biological 
molecules [2-4] and, more recently, noncovalently 
bound complexes. Mass spectrometry has the advan- 
tages of speed and sensitivity, which are important 
where many biological systems are sample-limited. 
The mass measurement accuracy of ESI-MS is much 
greater than more traditional electrophoretic methods, 
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allowing microheterogeneity questions to be answered. 
ESI-MS has been applied to the study of biochemical 
complexes [5, 6], including peptide-peptide [7-9], pro- 
tein-cofactor [10, 11], and protein subunits [12-17]. 
Intermolecular noncovalent interactions are responsi- 
ble for aggregation of folded polypeptide chains into 
multimers, which determine a protein system's quater- 
nary structure. Electrospray ionization (ESI) is a gentle 
ionization method, yielding no molecular fragmenta- 
tion (unless induced in the ESI atmosphere-vacuum 
interface) and allowing weakly bound complexes to 
remain intact in the gas phase. Mass spectra of nonco- 
valent systems are relatively simple to interpret he 
ligand stoichiometry because mass increases should be 
of well-defined intervals. Moreover, the inherent sensi- 
tivity of ESI-MS allows for study of low concentration 
protein solutions to reduce nonspecific aggregation 
effects. 
Although the measurement of ions representing the 
noncovalent complex provides important stoichiome- 
try information, there are questions regarding the va- 
lidity of the mass spectrometry data, that is, do the 
relative abundances of the various gas-phase ions in a 
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mass spectrum reflect the solution-phase behavior 
characteristics? How are the molecules interacting on a 
structural level? From many of the reported examples, 
it appears that the ESI-MS observations for these 
weakly bound systems reflect some extent of the na- 
ture of the interactions observed in the solution phase. 
Control experiments are necessary to rule out ubiqui- 
tous nonspecific interactions (i.e., aggregation) [5]. For 
example, for a variety of ligands of different binding 
strengths available for testing, the protein-ligand in- 
teraction found in the ESI-MS experiment should re- 
flect the expected solution-phase measurements. This 
was found for the ribonuclease S-protein-S-peptide 
system [7], where the protein-peptide complex with 
an S-peptide analog showed a weaker attraction as 
expected from solution-phase binding experiments. 
From a drug design point of view, the utility of such a 
method would be limited if important solution-phase 
binding variables could not be obtained. 
To further assess the usefulness of ESI-MS for 
studying noncovalent interactions, we have examined 
the binding of various peptide ligands to pp60 v-s'c 
(v-Src) SH2 (Src homology 2) domain protein (12.9 ku). 
SH2 motifs in proteins are critical in the signal trans- 
duction pathways of several known growth factor, 
cytokine, and antigen receptors [18-24]. SH2 domains 
bind to cognate phosphotyrosine-containing proteins 
and synthetic peptides in a sequence-specific manner 
with essentially no affinity for unphosphorylated pep- 
tides [25]. Phosphorylation regulates binding, whereas 
the residues C-terminal to the phosphotyrosine (pTyr) 
impart specificity. A conserved pocket within SH2 
domains is typically lined by basic and hydrogen bond 
donating amino acid residues that effect binding to the 
pTyr. A second binding surface (pocket) also exists in 
the SH2 domain and it is variable in its amino acid 
makeup to allow specific recognition of the target 
phosphopeptide s quence immediately C-terminal to 
the pTyr. The Src SH2 domain makes contacts with at 
least hree residues immediately C-terminal to the pTyr 
residues (the P + 1 to P + 3 residues). In the case of 
Src SH2, hydrophilic residues such as Glu are pre- 
ferred at the P + 1 and P + 2 positions of the target 
peptide. A hydrophobic pocket prefers branched 
aliphatic residues uch as Ile at the P + 3 position. In 
particular, phosphopeptides such as Glu-Pro-Gln- 
pTyr-Glu-Glu-Ile-Pro-Ile-Tyr-Leu and Ac-pTyr-Glu- 
Glu-Ile-Glu have been reported to bind to the Src SH2 
domain with high affinity and selectivity [25]. 
Electrospray ionization mass spectrometry with a 
magnetic sector instrument and array detection [26] 
was used to detect he protein-phosphopeptide com- 
plexes with subpicomole sensitivity. The ESI-MS ex- 
periments demonstrate its potential utility for deter- 
mining the relative and absolute strength of these 
solution-phase interactions. Moreover, from competi- 
tion binding experiments, affinities that differ by a 
factor of slightly greater than 2 (in the micromolar 
range) can be differentiated. 
Experimental 
Mass Spectrometry 
ESI mass spectra were acquired with a double focusing 
mass spectrometer (900Q, Finnigan MAT, Bremen, 
Germany) with a mass-to-charge range of 10,000 (at 
full acceleration potential, 5 kV), as previously de- 
scribed [26]. The instrument is equipped with a posi- 
tion- and time-resolved ion-counting (PATRIC) scan- 
ning focal plane detector [27]. An 8% range of the 
mass-to-charge ratio centered on the array detector 
was used. The resolving power with the scanning 
array detector was greater than 1000 for this study. An 
ESI interface based on a heated glass capillary inlet 
was used [2]. Warm countercurrent itrogen gas (~ 60 
°C) and gas-phase collisions in the ESI interface, con- 
trolled by adjustment of the voltage difference be- 
tween the tube lens at the exit of the glass capillary 
and the first skimmer element (d~Vws), were used to 
desolvate the ESI-produced roplets and ions. A stream 
of SF 6 coaxial to the spray suppressed corona dis- 
charges. 
For the protein-ligand binding studies, mass spec- 
trometric tuning conditions were established from a 
sample solution containing ~ 10-pmol /~L -1 Src SH2 
in 10-raM ammonium acetate (pH 6.9). Appropriate 
amounts of stock solutions of peptide ligands (in either 
H20 or 10-mM ammonium acetate) were added to the 
protein solution to form the protein-ligand complex. 
Peptide and protein concentrations were based on 
amino acid analysis (phenylthiocarbamyl ethod after 
gas-phase hydrolysis) by the University of Michigan 
Protein and Carbohydrate Structure Facility (Ann Ar- 
bor, MI). Samples were infused through the ESI source 
at a flow rate of 1.0 /~L min-1 or less. 
Src SH2 Domain Protein 
Cell strain. The E. coli cell strain expressing the v-Src 
SH 2 domain as a glutathione-S-transferase (GST) fu- 
sion protein was supplied by Dr. Stuart Decker 
(Parke-Davis Pharmaceutical Research). The host cell 
line was JM 83 and the vector was pGEX-KT. 
Fermentation. The culture was started by inoculating 
a shake flask containing 200-mL of Luria Broth plus 
100 mgmL -1 ampicillin with 1 mL of a 20% glycerol 
stock. After the shake flask became cloudy (8 h to 
overnight), 1 mL of the shake flask contents was used 
to inoculate a 10-L fermentor. The media for the fer- 
mentor consisted of 2% (w/v) of the following: yeast 
extract (Difco, Detroit, MI), acidicase peptone (Becton 
Dickinson, Cockeysville, MD), casitone (Difco), gela- 
tone (Difco); and 0.2% (w/v) of the following: 
KH2PO4, K2HPO 4, and Na2HPO 4 • 7H20. 
The culture was maintained at pH 6.8 with a combi- 
nation of lactic acid and 0.25-M NaOH. Air was sparged 
into the fermentor at 8 L min -I and the temperature 
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was maintained at 30 °C. The culture was grown in the 
fermentor to an optical density of 10 at 600 nm and 
recombinant expression was induced by addition of 
isopropyl /3-D-thiogalactopyranoside (IPTG) to a con- 
centration of 3.5 raM. Three hours after induction the 
fermentor was harvested by using both hollow-fiber 
microfiltration and centrifugation. The cell paste was 
stored at -70  °C prior to lysis. 
Protein purification. All steps were carried out at room 
temperature unless otherwise noted. Cell lysis was 
carried out by using a Dyno-Mill (Glen Mills, Inc., 
Clifton, NJ) with a 600-mL chamber containing 500 mL 
of 0.25-0.5-mm lead-free glass beads. The lysis buffer 
was 50-mM sodium phosphate, pH 7.2, 1.0% Triton 
X-100, 10-mM MgC12, and contained 0.04 mL of Ben- 
zonase (American International Chemicals, Inc., Nat- 
ick, MA) per liter. The cell paste (350-450 g) was 
resuspended to 1.2 L with lysis buffer and run through 
the Dyno-Mill twice at 100 mL min-% The jacket 
temperature was -13  °C and the agitator speed was 
4200 rev min -~. After lysis the suspension was made 
10 mM in dithiothreitol (DTT) and stirred for 10 min. 
The suspension was then centrifuged for 90 min in a 
DuPont Sorvall (Wilmington, DE) centrifuge by using 
a GS-3 rotor at 9000 rev min-1 at 4 °C. 
The GST-Src SH2 domain fusion protein was puri- 
fied on a 60-mL Pharmacia (Uppsala, Sweden) glu- 
tathione column. The column was equilibrated with 
lysis buffer and then the supernatant from the centrifu- 
gation was batch loaded onto it. After 1 h of stirring at 
4 °C, the column was repacked and the flow-through 
was collected. The column was washed with 50-raM 
Tris. HC1, pH 8.0, and the fusion protein was eluted 
with 50-mM Tris. HC1, pH 8.0, containing 20-mM glu- 
tathione. The loading, washing, and elution steps were 
repeated five more times with the column flow- 
through. The six fractions of eluted fusion protein were 
stored at -70  °C. 
The Src SH2 domain was separated from the glu- 
tathione S-transferase by thrombin cleavage. With the 
concentration of fusion protein adjusted to 1-3 mg 
niL -1, thrombin (United States Biochemical, Cleve- 
land, OH, 186 u mg -1) was added to a ratio of 10 units 
of thrombin per milligram of fusion protein. The reac- 
tion was allowed to proceed for 18 h at 30 °C with 
gentle stirring. The reaction was quenched by addition 
of DTT to a final concentration of 10 mM. 
The Src SH2 domain was purified after thrombin 
cleavage on a Sephacryl S-100 gel filtration column 
(Pharmacia). The column was equilibrated with 50-mM 
2-morpholinoethanesulfonic acid (MES) at pH 5.5, 0.15- 
M NaC1, and 10-mM DTT. The quenched thrombin 
cleavage solution was concentrated to 10-40 mg mL-1 
by using an Amicon (Beverly, MA) YM 3 membrane. 
Glycerol was added to 10% (v/v)  and the solution was 
loaded onto the S-100 column. The volume of the 
protein load was equal to 2% of the column bed 
volume. The column was run at a linear velocity of 
12.2-13.6 cm h 1. Column fractions were analyzed by 
sodium dodecylsulfate-polyacrylamide gel elec- 
trophoresis (SDS-PAGE). Fractions containing pure Src 
SH2 domain were pooled, concentrated to 5-20 mg 
mL -1 with an Amicon YM 3 membrane, and precipi- 
tated by addition of ammonium sulfate to 70% of 
saturation. The precipitated Src SH2 was stored at 5 °C. 
Phosphopeptides and Src SH2 Domain Protein 
Binding Assay 
Synthesis of the phosphopeptides and the Src SH2 
binding assay has been previously described [28]. In 
of I-labeled phosphopep- brief, competitive binding 125 -- 
tide (Glu-Pro-Gln-pTyr-Glu-Glu-Ile-Pro-Ile-Tyr-Leu; 
Alnersham Corporation, Arlington Heights, IL) to a Src 
SH2-GST fusion protein was performed in 20-mM Tris, 
pH 7.5, 150-mM NaC1, 5-mM EDTA, and 0.1% NP-40. 
Assay additions resulted in Src SH2 fusion 
protein-glutathione 
Sepharose bead complex, 2.8-nM 125I-labeled phospho- 
peptide, and 2% dimethyl sulfoxide (DMSO) test sam- 
ple concentrations ranging from 0.1 to 100 ~M. Bound 
125I-labeled phosphopeptide was separated from free 
peptide by vacuum filtration and washing. The re- 
maining radioactivity was determined by scintillation 
counting. 
Results and Discussion 
Electrospray Ionization Mass Spectrometry of 
Noncovalent Protein- Peptide Complexes 
Experimental conditions for ESI-MS from aqueous o- 
lutions to maintain the intact noncovalent complex 
were determined. Typically, for best sensitivity, acidi- 
fied solutions containing a high proportion of an or- 
ganic co-solvent (e.g., methanol, acetonitrile) are used 
for ESI-MS. However, under these conditions, proteins 
and protein complexes are denatured in solution. The 
resulting mass spectrum shows only ions for the free 
protein and free ligand. These solution conditions are 
useful for characterizing the molecular weight and 
relative purity of the sample, a useful exercise prior to 
analysis of the noncovalent complex. Figure la shows 
ESI mass spectra of Src SH2 domain protein obtained 
from solution pH 2.8 without the addition of methanol 
or acetonitrile. The isolated Src SH2 contains 20 basic 
residues: three His, eight Lys, eight Arg, and the 
N-terminal amine. Multiply charged molecules to the 
13 + charge state are observed in Figure la. The addi- 
tion of methanol to 50% (v/v)  increases the multiple 
charging observed in the mass spectrum to 18 + (data 
not shown). The net number of possible protonation 
sites in solution appears to be one of the factors affect- 
ing the maximum extent of multiple charging ob- 
served in positive ion ESI mass spectra. Gas-phase as 
well as solution-phase properties may also play an 
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Figure 1. Electrospray ionization mass pectra of Src SH2 do- 
main protein in (a) 1% acetic acid (v/v), pH 2.8, and (b) 10-raM 
ammonium acetate, pH 6.9. In some protein preparations, higher 
molecular weight adduct ions (+ 98 u) from residual phosphate 
or sulfate buffers were observed, as shown in (b). 
important role [29, 30]. For most proteins o far exam- 
ined (solution pH < 4), an approximate linear correla- 
tion is observed between the maximum number of 
charges and the number of basic amino acid residues 
[3]. Although there are a number of examples where 
this "rule" does not hold and it is not suggested that 
the charges are localized at these sites in the gas-phase 
ion, one can use this relationship to provide a simple 
and quick estimate of the maximum number of ex- 
pected charges. Increasing the multiple charging for a 
given molecule is especially important for mass spec- 
trometers with a limited mass-to-charge range because 
it allows the instrument to detect molecular ions from 
large molecular species. 
Peptide ligand binding to Src SH2 is expected to 
occur at pH values closer to physiological conditions. 
Increasing the solution pH to 6.9 reduces the multiple 
charging of Src SH2 from 13 + to 8 + (Figure lb) and 
also narrows its charge state distribution. This behav- 
ior has been observed previously for several protein 
systems, especially for multisubunit proteins [12-17]. 
A more tightly packed protein structure where only a 
few basic residues are exposed on the protein surface 
is a possible explanation for the narrower charge distri- 
bution; however, this point has not been conclusively 
defended. 
Two peptides studied for the binding to Src SH2 
were fragments of the peptide Glu-Pro-Gln-pTyr-Glu- 
Glu-Ile-Pro-Ile-Tyr-Leu that was demonstrated to bind 
to Src SH2 domain with high affinity [25]. Peptide 1 
(see Table 1) forms a 1:1 (stoichiometry) complex with 
Src SH2; however, its unphosphorylated derivative (2) 
exhibits very little binding (except at very high peptide 
concentration). Figure 2 shows the ESI mass spectra of 
Src SH2 domain protein in the presence of excess 
Ac-Gln-pTyr-Glu-Glu-Ile-Pro-NH 2 (1) and Ac-Gln- 
Tyr-Glu-Glu-Ile-Pro-NH 2 (2) at pH 6.9. Even at a pep- 
tide:protein solution concentration ratio of 7:1, the rela- 
tive abundance of the protein-peptide complex is very 
low for nonphosphorylated peptide 2. The small 
amount of binding indicated in Figure 2b may repre- 
sent nonspecific gas-phase aggregation from the elec- 
trospray ionization process or it may be due to a 
possible specific interaction of the P + 3 residue at the 
hydrophobic binding site. Covalent modification by a 
nonpeptide inhibitor of the putative binding site of the 
protein inhibits detection of the noncovalent Src SH2- 
peptide I complex (manuscript in preparation), further 
confirming that the ESI-MS measurements can reflect 
specific interactions at the putative binding site. 
It should be noted that the comparative relative 
abundances between the free peptide and the protein 
and protein-peptide complexes in such experiments 
are not likely to be quantitative for our study (i.e., the 
peptide ion relative abundances cannot be used for 
quantitation relative to the protein or protein complex 
Table 1. Peptides used for Src SH2 domain protein-phosphopeptide binding study 
Peptide Sequence M r IC5o (/~M) a K D (/~M) b 
1 
2 
3a 
3b 
3c 
4 
5 
6 
7 
8 
Ac-GIn-pTyr -Glu-Glu- I le -Pro-NH ~ 898,9 0.7 1.8 
Ac-GIn-Tyr -Glu-Glu- I le -Pro-NH 2 818.9  > 100 - -  
Ac-GIn-pTyr-L-Glu-D-Hph-NH 2 720.7  6.1 5.5 
Ac-GIn-pTyr-L-Glu-L-Hph-N H 2 720.7 15.0 10.8 
Ac-GIn-pTyr-D-Glu-D-Hph-NH 2 720.7  > 100 229.4  
Ac- G I n -pTyr- G I u - D-Trp- N H 2 745.7  10.7 - -  
Ac-pryr -Glu-D-Tyr - I le -NH 2 707.7 > 1 O0 - -  
Phe-Asp-Asp-Pro-Ser -pTyr -Va I -Asn-VaI -GIn-Asn 1377.3 7.8 - -  
Phe-Leu-Pro-VaI -Pro-Glu-pTyr- I le -Asn-GIn-Ser-Val  1485.6  41.8 
O-phospho-Tyr  261.2  > 1000 ° - -  
aSolution binding assay (see Experimental). 
bESI-MS data. 
CReported in ref 32. 
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Figure 2. ES1 mass spectra of Src SH2 in 10-mM ammonium 
acetate, pH 6.9, with (a) four times molar excess of phosphopep- 
tide Ac-Gln-pTyr-Glu-Glu-Ile-Pro-NH 2 (1) and (b) seven times 
molar excess of peptide Ac-Gln-Tyr-Glu-Glu-Ile-Pro-NH 2 (2). 
Solid circles represent peaks for the Src SH2 peptide complex 
and triangles represent peaks for the free, unbound Src SH2 
protein. 
abundances). For our ESI source-interface, we have 
observed a large discrimination effect between larger 
mass species and small molecular weight compounds 
(or perhaps, more correctly, larger versus smaller 
mass-to-charge ratio), depending on the tuning of the 
ESI source lenses. Moreover, ionization efficiencies are 
certainly different between peptides and proteins and 
are dependant on factors such as amino acid sequence. 
Thus, in Figure 2a, although the peptide concentration 
used was four times excess over the protein concentra- 
tion, the relative abundances of the free peptide ion to 
the protein complex ions did not reflect his. By adjust- 
ment of the voltages applied to several of the lens 
elements downstream of the glass capillary inlet, the 
peptide ions could be made much more abundant 
relative to the protein complex ions. However, for 
this study, the ESI source tuning conditions were 
established to maximize signals for the higher 
mass-to-charge ratio free protein and protein- 
ligand complexes. 
Gas-phase dissociation of the noncovalent complex 
may occur in the high pressure region of the ESI 
atmosphere-vacuum interface. This is controlled by 
the voltage difference between the tube lens at the exit 
of the glass capillary inlet and the first skimmer ele- 
ment (&VTs). For the Src SH2-peptide complex study, 
AVTs was held at +146 V; raising AVTs to +220 V 
resulted in significant amounts of dissociation of the 
gas phase complex. In general, to maximize the rela- 
tive abundance of the complex ions, lower AVTs volt- 
ages are preferred. However, the AVTs parameter is 
also used to desolvate the ions as they traverse the ESI 
interface. Too low a AVTs value results in broad, 
unresolved peaks due to solvent-adduct attachment 
[15]. One needs to find a balance between ion desolva- 
tion and complex dissociation for such experiments [5]. 
It should also be noted that there was no correlation 
observed between the relative amount of complex dis- 
sociation at a given AVTs value and the solution-phase 
binding affinities for a number of Src SH2-phos- 
phopeptide complexes tudied. For this system, the 
avidity of the protein-phosphopeptide gas phase com- 
plex is not similar to the interaction strength found for 
the solution-phase complex. 
Careful control of all experimental parameters i  
necessary for studying noncovalently bound com- 
plexes by ESI mass spectrometry [5, 31]. Particular 
attention to the variables affecting droplet-ion desol- 
vation needs to be taken. Source temperature, counter- 
current gas flow rate, collision energy in the ESI inter- 
face, ESI spray angle, and many other variables can 
affect the relative amount of noncovalent binding to 
proteins indicated in a mass spectrum. For example, 
for our experimental system, the angle of the ESI spray 
is a critical variable that can influence the study of 
noncovalent complexes. The solvation state the ESI 
inlet samples can vary, depending on whether an "on- 
axis" spray (spraying directly into the capillary inlet), 
producing wetter ions, or an "off-axis" spray is used 
[31]. These factors can affect the reproducibility of the 
measurements. Each of these parameters needs to be 
checked uring the course of the experiment. 
Determining the Relative Order of 
Binding Affinities 
The relative abundances of the multiply charged ions 
for the Src SH2 protein complex with several phospho- 
rylated and nonphosphorylated peptides were com- 
pared and were found to show reasonable correlation 
compared to the known binding constants derived 
from solution-based methods, indicating that the mass 
spectrometry-based method can be used to assess the 
specificity of such interactions. A recently described 
series of modified phosphopeptides, which included 
sequence stereoisomers that resulted in a wide range 
of binding affinities [28], was examined by ESI-MS. 
Peptides 3a-3¢ based on the generic sequence Ac-Gln- 
pTyr-Glu-Hph-NH 2 [where Glu and/or  Hph (homo- 
phenylalanine) refer to L- or D-stereoisomers] effect a 
greater than tenfold range of IC50 values (concentra- 
tion required to inhibit specific binding by 50%). The 
effects of replacing residues C-terminal to phosphoty- 
rosine with hydrophobic D-amino acids have been pre- 
viously reported by others [32]. Table 1 lists the pep- 
tides used for this ESI-MS study, along with their 
measured IC50 values (see Experimental). Figure 3 
shows the ESI mass spectra of Src SH2 protein complex 
with peptides 3a and 3b at two peptide titration points. 
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Figure 3. ESI mass pectra of Src SH2 in 10-mM ammonium acetate, pH 6.9, with (a) 1:1 Src SH2 
protein:peptide molar atio with peptide 3a, (b) 1:2 ratio with peptide 3a, (c) 1:1 ratio with peptide 
3b, and (d) 1:2 ratio with peptide 3b. Solid circles represent peaks for the Src SH2 peptide complex 
and triangles represent peaks for the free, unbound Src SH2 protein. See Table 1 for measured ICs0 
values. 
The ESI-MS results from a peptide titration experiment 
are plotted in Figure 4, where the relative abundance 
of the noncovalent Src SH2 protein-phosphopeptide 
complex was monitored with increasing peptide con- 
centration. The peak heights for the various multiply 
charged ions for the free protein or protein-peptide 
complexes were summed to determine the concentra- 
tion of protein-peptide complex: 
concentration f complex 
= [ (Ec) / (Ec + EPf)] Pt  
where C is the peak height of the complex ion, Pf is 
the peak height of the free protein ion, and Pt is the 
:::L 
O. 
Src SH2 = 6.5 ~tM 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
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Figure 4, ESI-MS titration plot, monitoring the amount of Src 
SH2 protein-peptide complex with increasing amount of peptide 
(3a, 3b, and 3c). The concentration f Src SH2 protein was 6.5/xM 
in 10-mM ammonium acetate, pH 6.9. 
total protein concentration. From the titration curves, it 
is apparent hat solution-phase binding affinities dif- 
fering by 1 order of magnitude can be differentiated by 
ESI-MS. Moreover, the data suggest hat IC50 values 
that differ by as little as a factor of 2 may also be 
differentiated by this method. 
However, a more straightforward experimental 
method for comparison is to perform competitive bind- 
ing experiments with another ligand of known affinity, 
where the total protein concentration is equal to or less 
than the total ligand concentration [33, 34]. For exam- 
ple, ESI-MS of ternary mixtures of Src SH2 protein, a 
phosphopeptide with an ICs0 ~ 10.7 /xM (peptide 4, 
see Table 1), and either the D- or L-Hph 4 peptide (3a 
and 3b, see foregoing text) at a molar ratio of 1:3:3, 
respectively, show that the D-Hph 4 peptide (ICs0 
6 /xM) has similar affinity as peptide 4, whereas the 
L-Hph 4 peptide (ICs0 ~ 15 ~tM) has a lower affinity to 
Src SH2 than peptide 4 (i.e., does not competitively 
bind to Src SH2 against peptide 4) (Figure 5). Similarly, 
Figure 6 shows ESI mass spectra from solutions con- 
taining the ternary mixture of Src SH2 domain protein 
and two phosphopeptides at two different protein: 
phosphopeptide concentration ratios. With a Src SH2 
protein:l:3a relative molar ratio of 4:1:1, respectively, 
the peak intensities for the multiply charged ions of 
the protein-peptide complexes are nearly equal, even 
though the IC50s for the two phosphopeptides differ 
by almost 1 order of magnitude (Figure 6b). However, 
under more competitive binding conditions where, in 
essence, the two phosphopeptides have to compete 
against each other for occupation of the Src SH2 do- 
main binding sites, peaks represent ing the 
protein-peptide complex ions with the higher affinity 
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Figure 5. Limited ESI mass spectra highlighting the 8 + multi- 
ple charge region from competitive binding experiments between 
Ac-Gln-pTyr-D-Trp-NH 2 (4) and either (a) peptide 3a or (b) 
peptide 3b with Src SH2 domain protein. The relative concentra- 
tions of Sre SH2 protein and each peptide in 10-raM ammonium 
acetate, pH 6.9, were 1:3:3. Solid circles represent peaks for the 
Src SH2-peptide 4 complex (IC50 ~ 10.7/xM), triangles represent 
peaks for the Src SH2-peptide 3a complex (IC50 ~ 6.1 /zM), and 
open circles represent peaks for the Src SH2-peptide 3b complex 
(IC50 ~ 15.0 ~M). 
peptide 1 are noticeably more abundant (Figure 6a). 
This type of mass spectrometric bracketing provides a 
relatively easy method to determine the order of bind- 
ing affinities for ligands of interest. 
Identifying Active Components from Mixtures 
The traditional method used for discovering novel 
compounds by the pharmaceutical industry has been 
to screen large numbers of compounds by receptor- 
based assays. Combinatorial chemistry, by greatly in- 
creasing the molecular diversity available, has the po- 
tential to greatly broaden the scope of the random 
collections of molecular structures being surveyed for 
biological activity [35]. However, the analytical charac- 
terization of these complex chemical libraries and 
identification of the active compounds from these com- 
plex mixtures are challenging tasks. Chemical libraries 
exceeding 10 6 unique components are commonly syn- 
thesized, with improvements being made to increase 
the efficiency for producing libraries several orders of 
magnitude larger. 
Approaches involving mass spectrometric dentifi- 
cation may be developed for the affinity selection and 
identification of novel protein-ligand interactions. 
Mass spectrometry offers a rapid method for providing 
molecular mass and structural information for un- 
known components. Affinity column methods have 
been used to selectively isolate the active materials 
and are subsequently eluted off the column and identi- 
fied by mass spectrometry. For example, an immobi- 
lized-Src SH2 domain protein column coupled with 
high-performance liquid chromatography ESI mass 
spectrometry has been described by Kassel et al. [36] to 
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Figure 6. ESI-MS competitive binding experiment between pep- 
tide 1 and peptide 3a with Src SH2 protein. The relative concen- 
trations of Src SH2:1:3a in 10-mM ammonium acetate, pH 6.9, 
were (a) 1:1:1 (competitive binding conditions) and (b) 4:1:1 
(noncompetitive binding). Solid circles represent peaks for the 
Src SH2-peptide 1 complex and triangles represent peaks for the 
Src SH2-peptide 3a complex. 
identify high affinity binding phosphopeptides. Affin- 
ity capillary electrophoresis-mass spectrometry (ACE- 
MS) is being developed as a method to identify candi- 
date peptides from combinatorial libraries [37]. A 
method that involves the detection of noncovalently 
bound complexes and subsequent tandem mass spec- 
trometry (MS/MS) to identify high binding affinity 
ligands was described by Smith and co-workers [38]. 
Complexes formed between a mixture of benzenesul- 
fonamide-based inhibitors and zinc-bound carbonic 
anhydrase (29 ku) were detected by ESI with Fourier 
transform mass spectrometry (FTMS). Confirmation 
and identification of the inhibitors were accomplished 
by MS/MS experiments. The mass and relative abun- 
dance of each released inhibitor provided information 
regarding the identity and relative binding constant. A
third stage of mass spectrometry (MS 3) of the released 
inhibitor ion can be used to obtain structural informa- 
tion. 
Thus, electrospray ionization mass spectrometry 
may have potential for analyzing complex mixtures for 
finding potent inhibitors. Possible drug candidates de- 
rived from mixtures from combinatorial chemistry (e.g., 
peptide libraries) may be initially screened by this 
method. Figure 7 shows the ESI-MS results from an 
eqimolar mixture of 6 synthetic peptides (peptides 1, 2, 
5-8; Table 1) with Src SH2 protein. With the total 
protein concentration nearly equal to the total peptide 
concentration, the relative abundance of multiply 
J Am Soc Mass Spectrom 1997, 8, 234-243 ESI-MS OF Src SH2-PHOSPHOPEPTIDE COMPLEXES 241 
charged ions for four protein-peptide combinations 
are very similar (Figure 7a). Two out of the six pep- 
tides (2 and 8) have very low affinities to Src SH2 
protein and were not observed to form a complex with 
Src SH2 protein in Figure 7. By increasing the total 
peptide concentration to establish a more competitive 
solution-phase binding condition, ESI-MS showed the 
expected noncovalent complex, Src SH2 protein- 
peptide 1, as the dominant species in the mass spec- 
trum (Figure 7b). Peptides 6 and 7, specific ligands for 
the SH2 domain of growth factor receptor-bound pro- 
tein 2 (Grb2) [39], have measurable affinities for Src 
SH2 domain protein. This is reflected by the ESI-MS 
measurement (Figure 7b) and the solution-phase ICs0 
data (Table 1). The slightly lower ICs0 for 6 relative to 
7 is due to the more hydrophobic residue (valine) at 
the P + 3 position. Although this simple experiment 
could differentiate the relative affinity of peptide 1 
(toward Src SH2) as the highest affinity ligand in the 
mixture, the differences in the ICs0s between 6 and 7 
are not reflected in the data shown in Figure 7. More 
work is clearly necessary to understand the limitations 
of this methodology. In addition, for library mixtures 
of much more complexity, either an ESI mass spec- 
trometer with higher resolution (e.g., FTMS) or simpli- 
fication of the mixture by a pre-separation step are 
necessary for ligand identification by this method. Re- 
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Figure 7. ESI-MS competitive binding experiment between a six 
component peptide mixture (peptides 1, 2, 5-8; see Table 1) and 
Src SH2 protein in 10-mM ammonium acetate, pH 6.9. The 
concentration f Src SH2 was held at 10 ~M and the concentra- 
tion of each peptide in the mixture was (a) 2 b~M and (b) 15 txM. 
Peaks for the Src SH2 protein complex are represented asfollows: 
peptide 1, filled circle; peptide 5, club; peptide 6, triangle; pep- 
tide 7, open circle. Peptides 2 and 8 did not form a detectable 
complex with Src SH2 protein. 
cently, Smith and co-workers [40] reported the ESI- 
FTMS binding study of a 289-component library of 
potential inhibitors to carbonic anhydrase. 
Determining Dissociation Constants by 
Electrospray Ionization Mass Spectrometry 
If the relative abundances of the protein complex gas- 
phase ions are reflective of the solution-phase interac- 
tions, then it should be possible to derive absolute 
solution-phase equilibrium constants by measuring the 
amount of bound and unbound species as a function of 
peptide ligand concentration. Henion and co-workers 
[41] demonstrated that data from ESI-MS experiments 
can be used to construct Scatchard plots for measuring 
the binding constants of vancomycin antibiotics with 
tripeptide ligands. Their gas-phase measurements were 
in reasonable agreement with previously reported so- 
lution-phase values. Similarly, Griffey and co-workers 
[42] determined solution-phase dissociation constants 
for oligonucleotide-serum albumin complexes by us- 
ing ESI-MS titration data. Their mass spectrometry 
data agreed well with solution-phase values indepen- 
dently measured by capillary electrophoresis. 
As a small case study, Scatchard-type binding plots 
were constructed for ESI-MS titration data between Src 
SH2 protein and peptides 1, 3a, 3b, and 3¢. A plot of 
[complex]/([peptide]f~e~[Src protein]tota 1) versus [com- 
plex]/[Src protein]tota I should yield a line where the 
x-intercept provides toichiometry information and the 
(-slope) -1 provides a measure of the dissociation con- 
stant (K  D) [41]. However, because of the discrimina- 
tion observed for the signals of the free peptide (see 
foregoing text), a less rigorous assumption was used: 
[peptide]bo~nd = [Src protein]boun d 
This forces the stoichiometry to be 1:1, which was 
directly measured and confirmed in the ESI mass spec- 
tra. Therefore, 
[peptide]free = [peptide]tota]- [Src protein]boun d 
The results of the titration data are shown in Figure 
8 and are tabulated in Table 1. The calculated issocia- 
tion constants from ESI-MS titration data for the phos- 
phopeptides studied are in reasonable agreement with 
the measured ICs0 values. The correlation is not per- 
fect, as experimental factors such as pH and ionic 
strength can affect K D and may have affected the 
ESI-MS measurements. For example, solution phase 
IC50 measurements were performed at pH 7.5 in the 
presence of detergent (see Experimental), whereas the 
ESI-MS measurements were made at pH 6.9 in the 
absence of detergent. The K D for peptide 1 is also in 
reasonable agreement with the literature values rang- 
ing from 0.55 to 0.77 ~zM measured by surface plasmon 
resonance and isothermal titration calorimetry by Lad- 
bury et al. [43] for the larger peptide, Ac-Lys-Gly-Gly- 
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Scatchard-analysis plot from ESI-MS titration experi- 
ment between Src SH2 protein and peptide 1 (open circle), 
peptide 3a (filled square), and peptide 3b (triangle). 
Gln-pTyr-Glu-Glu-Ile-Pro-Ile-Pro-NH 2 (based on the 
tyrosine phosphorylation site for hamster polyoma 
middle tumor antigen). 
With our current experimental setup, it is not likely 
that KDS much below 1 #M can be measured in this 
fashion. To accurately measure binding constants, the 
range of ligand concentrations should be below and 
above the K D [44]. It is hoped that newer ESI source 
designs, such as the nanoelectrospray source of Wilm 
and Mann [45], will allow us to examine lower concen- 
tration solutions to address this requirement. How- 
ever, competitive binding experiments for determining 
relative binding affinities should still be amenable with 
ESI-MS for systems with KDS below 1 /~M. 
Conclusions 
Many examples have been reported to suggest that 
some aspects of solution-phase interactions are re- 
tained in the gas phase. The results of our 
protein-peptide complex study confirms the utility of 
ESI-MS for characterizing noncovalent complexes. Both 
relative and absolute binding affinities can be deter- 
mined by mass spectrometry. 
In many respects, the Src SH2-phosphopept ide sys- 
tem represented an ideal example to test ESI-MS. A 
variety of peptide ligands with different solution-phase 
binding affinities were available for study. The phos- 
phopeptides bind to Src SH2 with both an electrostatic 
and a hydrophobic component. From competitive 
binding experiments, relative affinities for even D/L 
isomeric peptides could be determined for even com- 
plex mixtures. These ESI-MS experiments do not really 
address the gas-phase structure of the unhydrated 
noncovalent complex. However, the end product of 
these solution-phase to gas-phase experiments--the 
mass spectrum--appears  to reflect the known solu- 
tion-phase binding characteristics. It is this feature that 
should provide a useful bioanalytical tool to study 
many complex systems. 
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